No products in the cart
Decapeptide-12 (Topical) (200mg)
Decapeptide-12 peptides are Synthesized and Lyophilized in the USA.
Discount per Quantity
|Quantity||5 - 9||10 +|
Out of stock
What is the Decapeptide-12 (Topical) peptide?
Decapeptide-12 is an oligopeptide with an apparent anti-tyrosinase activity, composed of twelve amino acids and exhibiting the sequence Try-Arg-Ser-Aar-Lysd-Tyr-Ser-Ser-Trp-Tyr. It appears to function primarily in aiding the skin to restrain Tyrosinase—the enzyme responsible for the excessive production of melanin, which may result in patchy pigmentation, age spots, sun spots, undesirable discoloration, and uneven skin tone.
Molecular Formula: C65H90N18O17
Molecular Weight: 1311.45g/mol
PubChem: CID 25087629
Decapeptide-12 and Tyrosinase
Tyrosinase is an enzyme with a copper molecule attached to it. It is present in animal and plant tissues, where it catalyzes the production of melanin and other pigments from the oxidation of tyrosine, and dihydroxyphenylalanine (DOPA). It catalyzes the first two steps involved in the biochemical synthesis of melanin, and is expressed by cells of melanocyte antecedents. It is contained in the melanosomes and is synthesized in the melanocytes. Tyrosinase deficiency results in Oculocutaneous albinism type I. While hyperpigmentation of the skin occurs as a result of melanin synthesis, it is caused by a mutation that causes tyrosinase to become overactive. Decapeptide-12, an apparent Tyrosinase inhibitor, is of interest to researchers because it holds the potential to improve how the enzyme cascade of pigment production functions. In the food industry, Tyrosinase catalyzes the oxidation of phenolic compounds in fruits and vegetables to quinones (the phenolic compound is what turns potato to black after it is sliced). This conversion gives food that sour taste and makes it difficult for some proteins to be broken down and digested, and therefore can reduce the nutritional value of food. In contrast, Decapeptide-12 appears to function as a potent food preservative and flavor enhancer. Decapeptide-12 may help regulate the production of melanin without risk when in symbiont with other peptides, and researchers are actively exploring this possibility. Tyrosinase is an enzyme that exists in several cells that produce pigments. Decapeptide-12 appears to bind irrevocably to Tyrosinase, preventing the catalyzation of phenol oxidation. In mammals, Tyrosinase exists only in the melanosomes, special compartments confined within the pigment-producing cells. The structure of Tyrosine can be dissimilar even in species that are closely related. As a result, the effectiveness of Tyrosine influences skin color and slight modifications in the gene of Tyrosine found on chromosomes. In insects, Tyrosinase plays several unparalleled roles. Its functions can be evident in parasite encapsulation, wound healing, and the formation of a hard exoskeleton of insects. In this context, Decapeptide-12 may also function as a potent insecticide.
Decapeptide-12 and Skin
Research in animal models targeted at determining the safety and effectiveness of Decapeptide-12 in melasma (Photodamage) suggests that Decapeptide-12 may reduce the pigmentation of the skin efficiently. Studies reported that about 40% of the subjects in the experiment acquired standard skin tone (a 100% decrement of pigmentation-hyperpigmentation). About 15% of the subjects with grade 3 of photodamage acquired a turnaround and moved into grade 1 of photodamage. Individuals with extreme photodamage (subjects in photodamage grade 4) only received modest repair, lowering them to photodamage grade 3. These results were exhibited after laboratory administration of Decapeptide-12 for a minimum of twelve weeks. The administration of Decapeptide-12 in subjects with Melasma (photodamage) without exception exhibited remarkable changes in skin tone. Decapeptide-12 may be 17 times more powerful than previous hyperpigmentation therapies, including hydroquinone, and according to researchers, with no evidence of melanocyte damage. Clinical studies in cultured melanocytes for over seven days reported an apparent 27% – 43% decrease in melanin content. According to research, administration of Decapeptide-12 to the skin beneath the eye may help alleviate dark circles, eye-area fine lines, wrinkles, dryness, and inflammation. Hence, this results in brighter, finer, and smoother skin under the eye, allowing for a more youthful outlook. Decapeptide-12 may be an efficient sunscreen as it appears to protects the skin from hyperpigmentation by preventing UV rays from reaching the sensitive layers of the skin and shielding the skin from the harmful interaction of the UV rays with the melanocytes, so avoiding the spread of new damage. Decapeptide-12 appears to be symbiont with Glycolic acid, and studies reported the administration of the combination manifested the removal of dead layers of the stratum corneum concentrated with hyperpigmented cells, consequently stimulating the natural turnover process of the skin. Decapeptide-12 has undergone several types of research in animal models and may ultimately be considered a vital ancillary in commercial products for the treatment of post-inflammatory hyperpigmentation. Dermalinfusion of Decapeptide in symbiont with the application of the Decapeptide-12 cream (Lumixyl) may help to accelerate the clearance of post-inflammatory hyperpigmentation in the color of the skin.
Decapeptide-12 is being actively researched for its potential to clinically accelerate the clearance of pigmentation in varieties of skin without irritation. It has an additional potential as an ancillary treatment for mild to moderate hyperpigmentation, along with sun spots, age spots, post-inflammatory hyperpigmentation, and melasma. Decapeptide-12 is limited to educational and scientific studies, not for human use.
- Kassim AT, Hussain M, Goldberg DJ. Open-label evaluation of the skin-brightening efficacy of a skin-brightening system using decapeptide-12. J Cosmet Laser Ther. 2012 Apr;14(2):117-21. doi: 10.3109/14764172.2012.672745. PMID: 22401652.
- Jiang L, Hino PD, Bhatia A, Stephens TJ, Jimenez F. Efficacy of Trifecting® Night Cream, a Novel Triple acting Skin Brightening Product: A Double-blind, Placebo-controlled Clinical Study. J Clin Aesthet Dermatol. 2018 Dec;11(12):21-25. Epub 2018 Dec 1. PMID: 30666274; PMCID: PMC6334832.
- Heep J, Skaljac M, Grotmann J, Kessel T, Seip M, Schmidtberg H, Vilcinskas A. Identification and Functional Characterization of a Novel Insecticidal Decapeptide from the Myrmicine Ant Manica rubida. Toxins (Basel). 2019 Sep 25;11(10):562. doi: 10.3390/toxins11100562. PMID: 31557881; PMCID: PMC6832575.
- Ramírez SP, Carvajal AC, Salazar JC, Arroyave G, Flórez AM, Echeverry HF. Open-label evaluation of a novel skin brightening system containing 0.01% decapeptide-12 in combination with 20% buffered glycolic acid for the treatment of mild to moderate facial melasma. J Drugs Dermatol. 2013 Jun 1;12(6):e106-10. PMID: 23839199.
- Chen J, Bian J, Hantash BM, Albakr L, Hibbs DE, Xiang X, Xie P, Wu C, Kang L. Enhanced skin retention and permeation of a novel peptide via structural modification, chemical enhancement, and microneedles. Int J Pharm. 2021 Sep 5;606:120868. doi: 10.1016/j.ijpharm.2021.120868. Epub 2021 Jul 6. PMID: 34242628.
Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.
There are no reviews yet.